Running a clinical study is complicated. From a regulatory compliance…perspective you need to know what type of study it is. This drives the direction of ‘what you need to do’ (regulatory compliance) versus what you ‘should’ do (best practice considerations).
As discussed previously, definitions, or more correctly ‘regulatory definitions’, are very important. These definitions (e.g., non-interventional study) describe the boundaries of the study (what the study is and is not) and direct researchers to the applicable regulations and guidelines (hopefully).
When you intend to conduct of clinical study to answer a research question, it is important that you understand what the clinical study is. Is it…(1) a clinical trial, (2) a non-interventional (drug) study, or (3) an observational study (e.g., natural history study)?
Why are these questions important? Each of these three clinical study types are regulated differently…and to make matters worse…the regulatory framework for non-interventional (drug) studies and observational (disease) studies is different…in every country…globally.
For example, regulatory compliance considerations include:
[1] Clinical Trials = Clinical trial regulations + compliance with ICH GCP (very similar requirements globally)
[2] Non-Interventional Study = Local biomedical research regulations + pharmacovigilance requirements + consideration of/ compliance with best practices (e.g., ISPE GPP, ENCePP Guide on Methodological Standards in Pharmacoepidemiology etc )
[3] Observational Study = Local biomedical research regulations
As you can see, the regulatory requirements for clinical trials are very different to those for non-interventional (drug) studies and observational (not drug) studies. Knowing what type of clinical study (regulatory classification) you intend to run is key to understanding what your regulatory obligations are, who you need to get approvals from, who you need to notify, what you need to notify…and what you need to tell patients so that they are adequately informed before they make the decision to participate in your research.
In summary, recognizing (correctly classifying) the study type is crucial for fulfilling regulatory obligations, obtaining necessary approvals, notifying relevant parties, and ensuring informed patient participation.
Share this story...
Lithuania – Leaping into Digital Health Future with RWE and RWD Innovations
RWE 201 - Lithuania – Leaping into Digital Health Future with RWE and RWD Innovations EU Partnership Agreement: https://ec.europa.eu/commission/presscorner/detail/en/ip_22_2547Lithuania is actively implementing Real-World Evidence (RWE) and Real-World Data (RWD) [...]
RWE Guest Post – Does Real-World Evidence Play a Role in G-BA’s Benefit Assessments in Germany?
RWE 201 - RWE Guest Post - Does real-world evidence play a role in G-BA's benefit assessments in Germany? Guest: Anja PownellGerman Market Access – Simplified: https://germanmarketaccesssimplified.com/IntroductionThe German [...]
RWE Guest Post – Germany – From Concept to Evaluation: The Journey of RWE requests by the G-BA
RWE 201 - RWE Guest Post – Germany - From Concept to Evaluation: The Journey of RWE requests by the G-BA Guest: Anja PownellGerman Market Access – Simplified: [...]
Spain – Championing the Ethical and Responsible Use of Real World Data
RWE 201 - Spain – Championing the Ethical and Responsible Use of Real World Data Farmindustria Code of Conduct: https://codigoprotecciondatos.farmaindustria.org/sites/medicamentosinnovadores/docs/PRODF484450.pdfIn 2022, the Spanish Data Protection Agency (AEPD) gave its [...]
EU – RWD/RWE is Embedded into the New EU Medicines Regulations
RWE 201 - EU – RWD/RWE is Embedded into the New EU Medicines Regulations Coming Soon…New EU Medicines Regulations: https://health.ec.europa.eu/medicinal-products/pharmaceutical-strategy-europe/reform-eu-pharmaceutical-legislation_enIn 2023, the European Commission undertook an ambitious overhaul of [...]
EU – EU’s Action Plan for Real-World Data (RWD) & RWE
RWE 201 - EU – EU's Action Plan for Real-World Data (RWD) & RWE The European Union has embarked on an ambitious journey to weave Real World Evidence (RWE) [...]







